Comparative Pharmacology
Head-to-head clinical analysis: ENFLURANE versus SUPRANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENFLURANE versus SUPRANE.
ENFLURANE vs SUPRANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Enflurane is a volatile halogenated ether that potentiates GABA-A receptor activity, inhibits NMDA receptors, and enhances glycine receptor function, leading to generalized central nervous system depression and anesthesia.
Suprane (desflurane) is a volatile general anesthetic that potentiates GABA-A receptor activity and inhibits NMDA receptor function, leading to neuronal hyperpolarization and depression of central nervous system activity.
Induction: 0.5-4.5% inspired concentration; Maintenance: 0.5-3% inspired concentration with oxygen/nitrous oxide; via inhalation.
Induction: 0.5-3% inspired concentration in oxygen or oxygen/nitrous oxide mixture; Maintenance: 0.5-2% inspired concentration. Administered via inhalation using a calibrated vaporizer.
None Documented
None Documented
Clinical Note
moderateEnflurane + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Enflurane is combined with Fluticasone propionate."
Clinical Note
moderateEnflurane + Methylphenidate
"Enflurane may increase the hypertensive activities of Methylphenidate."
Clinical Note
moderateEnflurane + Clotrimazole
"The metabolism of Clotrimazole can be decreased when combined with Enflurane."
Clinical Note
moderateEnflurane + Clemastine
Terminal elimination half-life is approximately 4-8 hours in adults; context: prolonged with obesity due to high lipid solubility and storage in adipose tissue.
Context-sensitive half-life: 2-5 minutes after brief administration; prolonged to 20-40 minutes after prolonged administration due to slow release from fat stores.
Primarily eliminated by pulmonary excretion as unchanged drug (>90%); less than 5% is metabolized via CYP2E1 to fluoride ions and other metabolites, which are renally excreted.
Primarily eliminated by the lungs with minimal metabolism (<5%). Less than 0.2% of the absorbed dose is excreted renally as unchanged drug.
Category C
Category C
Inhalational Anesthetic
Inhalational Anesthetic
"The risk or severity of adverse effects can be increased when Enflurane is combined with Clemastine."